<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>Leeds Institute of Molecular Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/510575A8-0955-42BF-8DE8-17C407840AE0"><gtr:id>510575A8-0955-42BF-8DE8-17C407840AE0</gtr:id><gtr:firstName>Fiona</gtr:firstName><gtr:surname>Collinson</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700549"><gtr:id>3BFD2087-F24D-4F26-B9CE-3F4BC2B6F474</gtr:id><gtr:title>The identification and validation of novel biomarkers of ovarian cancer utilising proteomic techniques</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0700549</gtr:grantReference><gtr:abstractText>Ovarian cancer is the fourth commonest female cancer and has an associated high death rate. Patients diagnosed with early disease live longer compared to those diagnosed with advanced disease where it has spread to other sites in the body. Unfortunately ovarian cancer is difficult to diagnose early. We therefore need to find new markers, substances produced by the cancer, which we can measure in the blood to help diagnose it early, as well as to predict its behaviour and diagnose when it has come back. 
Cancerous and normal ovarian cells can be grown in the laboratory. We can collect the fluid they have grown in and examine the substances produced by the cells or embedded in the surface of the cells. Any substances we find only produced by cancer cells may also be produced by cancers in the body and act as markers. 
Any markers found can then be studied in the blood and may help to diagnose the cancer earlier or tell us when the cancer has returned, both of which means the patient may get treatment earlier or may help us decide which treatment is best for a specific patient.</gtr:abstractText><gtr:technicalSummary>Aims: To identify and validate potential biomarkers relating to ovarian cancer. 

Objectives: 
 
 Identify proteins which are differentially present in a). the conditioned media of malignant ovarian cells compared with normal ovarian cells (IOSE - immortalised ovarian surface epithelial cell lines) and b). enriched plasma membrane protein fractions from these cells
 Carry out initial validation of the differential expression and determine potential clinical utility using tissue and serum/plasma samples from patients with ovarian cancer and benign gynaecological conditions

Methodology: Malignant ovarian cells (established ovarian cancer cell lines and primary ovarian cancer cells isolated from ascitic fluid) and normal IOSE will be cultured, serum starved for 24 hours and the conditioned media produced, harvested and processed and profiled using 2D-DIGE (differential in gel electrophoresis) with a fluorescently labelled control pool on each gel comparison. Differentially expressed proteins will be sequenced by tandem mass spectrometry. 

In parallel, ovarian cell lines as above will be cultured using SILAC reagents (stable isotope labelling with amino acid in cell culture), sub-fractionated using cell surface biotinylation to enrich for membrane proteins, samples mixed for appropriate pair-wise comparison and proteins separated by 1D-PAGE. Lane slices (30) will be subjected to tryptic digestion and quantitative comparison undertaken using LC-MS/MS. 

Initial validation of putative differentially expressed proteins will be achieved by Western blotting and immunocytochemistry using the cell lines and/or media. Subsequent validation will involve immunohistochemistry using banked tissue samples (ovarian cancer, benign and normal controls including a range of normal tissue types) to examine the specificity of tissue expression, and research grade immunoassay development and quantitation in serum/plasma samples from our sample bank for selected markers. Those with clinical utility will also ultimately be assessed in the ICON7 trial samples. 

Scientific and medical opportunities of the study: Ovarian cancer normally presents at an incurable advanced stage due to non-specific signs and symptoms. At present there is no effective screening method. CA125 is the standard tumour marker but lacks specificity and is mainly used for monitoring patients longitudinally. However it is uninformative in about 20% of patients in this regard. There is a clear need for early diagnostic markers, as well as improved markers to aid in prognostication, monitoring response to therapy and longitudinal monitoring. This research project has the potential to deliver clinically useful markers but such may also provide new potential therapeutic targets, either directly or by providing insight into the underlying biological changes.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>128404</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Clinical Lectureship</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>11A83C3C-2977-479D-ACBB-CE6B63FF23C9</gtr:id><gtr:outcomeId>dX8cWJ9kzEm0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>FE5BD530-3F8A-4D39-B786-BEC4282E975A</gtr:id><gtr:title>Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c79ea24fa0bf39b3c4ebfb2454e5726"><gtr:id>0c79ea24fa0bf39b3c4ebfb2454e5726</gtr:id><gtr:otherNames>Collinson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_12642_22_23935036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBAD7E41-C1AF-475F-99E8-9CD4A15A181F</gtr:id><gtr:title>Development of antiangiogenic agents for ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e243ec55c496217aa615acb84169ab4e"><gtr:id>e243ec55c496217aa615acb84169ab4e</gtr:id><gtr:otherNames>Collinson FJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>NVDa6JbRGqQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>712981A5-25D2-4A6C-8FC6-C22401E5ED64</gtr:id><gtr:title>New therapeutic agents in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in obstetrics &amp; gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c79ea24fa0bf39b3c4ebfb2454e5726"><gtr:id>0c79ea24fa0bf39b3c4ebfb2454e5726</gtr:id><gtr:otherNames>Collinson F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1040-872X</gtr:issn><gtr:outcomeId>dDYVJtzCSZX</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700549</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>